Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1971 2
2006 1
2008 1
2012 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, Chung C, Wong P, Lehane PB, Tyrrell H. Keystone EC, et al. Among authors: loveless je. J Rheumatol. 2012 Dec;39(12):2238-46. doi: 10.3899/jrheum.120573. Epub 2012 Oct 1. J Rheumatol. 2012. PMID: 23027887 Free article. Clinical Trial.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group. Cohen SB, et al. Among authors: loveless je. Arthritis Rheum. 2006 Sep;54(9):2793-806. doi: 10.1002/art.22025. Arthritis Rheum. 2006. PMID: 16947627 Free article. Clinical Trial.
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.
Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, Tak PP, Broder MS, Yu E, Cravets M, Magrini F, Jost F. Keystone E, et al. Among authors: loveless je. Arthritis Rheum. 2008 Jun 15;59(6):785-93. doi: 10.1002/art.23715. Arthritis Rheum. 2008. PMID: 18512710 Free article. Clinical Trial.